This product is handled exclusively in controlled research settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine

Key Insights Fatigue is a common but usually temporary side effect during the initial weeks or dose changes in GLP-1 therapy, caused largely by rapid calorie deficit, dehydration, and metabolic adjustments. Maintaining steady energy requires prioritising nutrient-dense meals rich in protein and complex carbohydrates, staying well hydrated, and managing electrolyte balance, which helps mitigate tiredness and supports overall metabolism. Gentle physical activity and good sleep hygiene are critical lifestyle adjustments that improve circulation, mood, and energy levels without overtaxing the body during the drug adaptation period. Persistent, worsening, or debilitating fatigue should prompt medical evaluation to exclude other causes, reassess medication dosing, and ensure safe continuation of GLP-1 therapy under healthcare supervision. Frequently asked questions Why do GLP-1 medications cause fatigue

SaVanna Shoemaker, MS, RDN, LD Tester SaVanna Shoemaker is a registered dietitian and health writer
Soluble heparin-binding epidermal growth factor (sHB-EGF) is another target in combating cancer tumorigenesis and metastasis